Search

Author/Creator List, Alan F.

1. A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. (6th July 2013)

Authors:
Ostronoff, Fabiana; Othus, Megan; Kantarjian, Hagop M.; Meshinchi, Soheil; Ravandi, Farhad; Hendrie, Paul C.; Faderl, Stefan; Becker, Pamela S.; Cortes, Jorge E.; Pagel, John M.; Petersdorf, Stephen H.; Godwin, John E.; Willman, Cheryl L.; Pierce, Sherry A.; List, Alan F.; Sandhu, Ravinder K.; Wa...
Journal:
British journal of haematology
Issue:
Volume 163:Number 1(2013:Oct.)
Page Start:
130
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. Issue 9 (14th August 2015)

Authors:
Griffin, Patrick T.; Komrokji, Rami S.; De Castro, Carlos M.; Rizzieri, David A.; Melchert, Magda; List, Alan F.; Lancet, Jeffrey E.
Journal:
American journal of hematology
Issue:
Volume 90:Issue 9(2015:Sep.)
Page Start:
796
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Issue 8 (2nd July 2020)

Authors:
Duong, Vu H.; Al Ali, Najla; Zhang, Ling; Padron, Eric; Sallman, David; Lancet, Jeffrey E.; List, Alan F.; Komrokji, Rami S.
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 8(2020)
Page Start:
1901
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. (23rd January 2018)

Authors:
McGraw, Kathy L.; Nguyen, Johnny; Al Ali, Najla H.; Komrokji, Rami S.; Sallman, David; Zhang, Xiaohui; Song, Jinming; Padron, Eric; Lancet, Jeffrey E.; Moscinski, Lynn C.; List, Alan F.; Zhang, Ling
Journal:
British journal of haematology
Issue:
Volume 184:Number 3(2019)
Page Start:
450
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Autoimmune diseases and myelodysplastic syndromes. Issue 5 (4th April 2016)

Authors:
Komrokji, Rami S.; Kulasekararaj, Austin; Al Ali, Najla H.; Kordasti, Shahram; Bart‐Smith, Emily; Craig, Benjamin M.; Padron, Eric; Zhang, Ling; Lancet, Jeffrey E.; Pinilla‐Ibarz, Javier; List, Alan F.; Mufti, Ghulam J.; Epling‐Burnette, Pearlie K.
Journal:
American journal of hematology
Issue:
Volume 91:Issue 5(2016:May)
Page Start:
E280
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double‐induction chemotherapy: Analysis from a large, single institution experience. Issue 3 (3rd February 2017)

Authors:
Griffin, Patrick T.; Komrokji, Rami S.; Sweet, Kendra; Al Ali, Najla H.; Padron, Eric; Kubal, Timothy E.; List, Alan F.; Lancet, Jeffrey E.
Journal:
American journal of hematology
Issue:
Volume 92:Issue 3(2017:Mar.)
Page Start:
232
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes. (28th January 2014)

Authors:
Seymour, John F.; Bennett, John M.; List, Alan F.; Mufti, Ghulam J.; Gore, Steven D.; Fenaux, Pierre; Santini, Valeria; Hetzer, Joel; Songer, Stephen; Skikne, Barry S.; Beach, Charles L.
Journal:
British journal of haematology
Issue:
Volume 165:Number 1(2014:Apr.)
Page Start:
49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?. Issue 11 (November 2015)

Authors:
Zeidan, Amer M.; Sekeres, Mikkael A.; Wang, Xiao‐Feng; Al Ali, Najla; Garcia‐Manero, Guillermo; Steensma, David P.; Roboz, Gail; Barnard, John; Padron, Eric; DeZern, Amy; Maciejewski, Jaroslaw P.; List, Alan F.; Komrokji, Rami S.; on Behalf of the MDS Clinical Research Consortium (Funded by Edwar...
Journal:
American journal of hematology
Issue:
Volume 90:Issue 11(2015:Nov.)
Page Start:
1036
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Issue 6 (11th May 2020)

Authors:
Nguyen, Lynh; Zhang, Xiaohui; Roberts, Evans; Yun, Seongseok; McGraw, Kathy; Abraham, Ivo; Song, Jinming; Braswell, Diana; Qin, Dahui; Sallman, David A.; Lancet, Jeffrey E.; List, Alan F.; Moscinski, Lynn C.; Padron, Eric; Zhang, Ling
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 6(2020)
Page Start:
1395
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗